Associations of and gene polymorphism with ulinastatin efficacy in patients with severe acute pancreatitis.

We aim to explore the associations between matrix metalloproteinase (MMP) gene polymorphism with ulinastatin (UTI) efficacy in treating severe acute pancreatitis (SAP). A total of 276 SAP patients were assigned into the control (=135) and observation (=141) groups. PCR-restriction fragment length polymorphism (PCR-RFLP) was used for genotype and allele frequency distribution. Relevance of genotypes with UTI efficacy was analyzed. The observation group showed lowered duration in symptoms (abdominal distension, abdominal pain, tenderness, and rebound tenderness) than the control group. Laboratory analysis (serum calcium, white blood cells, serum amylase, urine amylase, APACHE-II, and Balthazar CTIS scores) were decreased, while serum albumin levels increased after 7th day of therapy. The total effective rate of UTI for patients with C-1306T C/C genotype was higher than those with C/T and T/T genotypes after the 7th day of therapy, which was lower in patients with C-1562T C/C and C/T genotypes than those with T/T genotype. The duration for symptoms in patients with C-1562T T/T genotype was shorter than those with C/C and C/T genotypes, which was less in patients with C-1306T C/C genotype than those with C/T and T/T genotypes. The improvement values of APACHE-II and Balthazar CTIS scores for patients with C-1306T C/C genotype were higher than those with C/T and T/T genotypes, which for patients with C-1562T C/C and C/T genotypes were lower than those with T/T genotype. These results demonstrated that gene polymorphism was associated with UTI efficacy for SAP.